Azadeh karami biography sampler
•
Articles
Associations of thyroid hormone serum levels with in-vivo Alzheimer’s disease pathologies
The present study investigated the relationships between thyroid hormone serum levels or thyroid-stimulating hormone (TSH) and two Alzheimer’s disease (AD)-specific biomarkers, cerebral amyloid beta (Aβ) burde...
Authors: Hyo Jung Choi, Min Soo Byun, Dahyun Yi, Bo Kyung Sohn, Jun Ho Lee, Jun-Young Lee, Yu Kyung Kim and Dong Young Lee
Citation:Alzheimer's Research & Therapy 2017 9:64
Content type: ResearchPublished on: 17 August 2017
Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer’s disease with and without cerebrovascular disease
Mixed vascular and neurodegenerative dementia, such as Alzheimer’s disease (AD) with concomitant cerebrovascular disease, has emerged as the leading cause of age-related cognitive impairment. The brain white m...
Authors: Fang Ji, Ofer Pasternak, Siwei
•
Important dates
Onsite registration: August 23rd 2024 (midnight CEST)
Online registration: September 30th 2024 (midnight CEST)
Description
This workshop is part of the MDDB project.
In only a few decades the Molecular Dynamics (MD) world has moved from a field dominated by a few highly specialized groups with a deep knowledge of the technology, who are typically method and software developers, to a situation where MD is present in many more areas of science, including biology. Molecular mechanics is used to relax models e.g. in AlphaFold, a number of experimental techniques like Cryo-EM and NMR now regularly combine their data with simulations, and we are seeing an emergence of data-driven modeling where huge amounts of experimental data e.g. from mutation studies or genome sequencing are combined with simulations (not least during the Covid-19 pandemic). On the one grabb, the field has seen tremendous progress with much more accurate force-fields, the development of more
•
CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
Introduction
The central cholinergic pathways have prominent roles in learning and memory. The severity of cholinergic deficits in patients with Alzheimer’s disease (AD) correlates with cognitive impairment, which have led to the development of cholinesterase inhibitors (ChEIs). The currently registered ChEIs as AD therapeutics putatively act by inhibiting the degradation of acetylcholine (ACh) in the synaptic cleft by the synaptic acetylcholinesterase (AChE), prolonging ACh’s action on its receptors (AChRs; Darreh-Shori and Soininen, 2010).
ChEIs are in use as symptomatic therapy in patients with AD for decades now. Still there are major gaps in our understanding of the in vivo biodynamic processes that may account for their limited clinical efficacies, possible disease-modifying effect or development of tolerance against these drugs.
There are three registered ChE